Literature DB >> 14977211

Neuroprotection and glatiramer acetate: the possible role in the treatment of multiple sclerosis.

Tjalf Ziemssen1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14977211     DOI: 10.1007/978-1-4419-8969-7_7

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


× No keyword cloud information.
  5 in total

Review 1.  Modulating processes within the central nervous system is central to therapeutic control of multiple sclerosis.

Authors:  Tjalf Ziemssen
Journal:  J Neurol       Date:  2005-11       Impact factor: 4.849

2.  Basic and escalating immunomodulatory treatments in multiple sclerosis: current therapeutic recommendations.

Authors:  H Wiendl; K V Toyka; P Rieckmann; R Gold; H-P Hartung; R Hohlfeld
Journal:  J Neurol       Date:  2008-10-29       Impact factor: 4.849

Review 3.  Purely systemically active anti-inflammatory treatments are adequate to control multiple sclerosis.

Authors:  Hans-Peter Hartung; Bernd C Kieseier; Bernhard Hemmer
Journal:  J Neurol       Date:  2005-11       Impact factor: 4.849

4.  [Escalating immunomodulatory therapy of multiple sclerosis. Update (September 2006)].

Authors:  Peter Rieckmann
Journal:  Nervenarzt       Date:  2006-12       Impact factor: 1.214

Review 5.  Optimizing treatment success in multiple sclerosis.

Authors:  Tjalf Ziemssen; Tobias Derfuss; Nicola de Stefano; Gavin Giovannoni; Filipe Palavra; Davorka Tomic; Tim Vollmer; Sven Schippling
Journal:  J Neurol       Date:  2015-12-24       Impact factor: 4.849

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.